Department of Orthopedics, China-Japan Union Hospital, Jilin University, Changchun, 130033, PR China.
Department of Anesthesiology, China-Japan Union Hospital, Jilin University, Changchun, 130033, PR China.
Eur J Pharmacol. 2019 Jul 5;854:298-306. doi: 10.1016/j.ejphar.2019.03.034. Epub 2019 Apr 10.
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the authors and the Editor-in-Chief as the validity of the data cannot be guaranteed. The journal was initially contacted by the corresponding author to report that, when the authors verified post publication PTEN as their former target of miR-140-3p, they found that treatment with miR-140-3p or miR-155-5p antagomir increased PTEN protein levels in patient-derived chordoma cells without having a significant effect on the malignancy of the tumor cells. The journal further requested the author to provide more information about their post publication findings with regard to this article. However, the author was not able to fulfil this request.
请参阅爱思唯尔关于文章撤回的政策(http://www.elsevier.com/locate/withdrawalpolicy)。应作者和主编的要求,撤回了本文,因为数据的有效性无法保证。期刊最初联系了通讯作者,报告说当作者验证 miR-140-3p 的 PTEN 作为他们以前的靶标时,他们发现用 miR-140-3p 或 miR-155-5p 反义核苷酸处理患者来源的脊索瘤细胞会增加 PTEN 蛋白水平,而对肿瘤细胞的恶性没有显著影响。期刊进一步要求作者就本文提供更多关于他们发表后发现的信息。然而,作者无法满足这一要求。